Developing a high throughput AlphaLISA assay for screening activity of biologics produced by engineered probiotic microbes

Due to limitations driven by circulatory half-life and drug target bioavailability, injected biologics often require the injection of high doses, which can result in patient discomfort, unwanted side effects, a limited therapeutic window, and higher costs. To sidestep these pain points, Tenza has engineered probiotic microbes to synthesize and deliver protein therapeutics directly to the target tissue.

The functional activity of the secreted protein biologic is assessed by its binding to a target protein relevant to its therapeutic indication. The pre-existing assay format for testing functional activity was a standard ELISA, which had limited dynamic range and throughput, required large sample volumes, and involved multiple tedious wash steps.

Download this application note and discover how the authors switched to a custom developed AlphaLISA^® assay to overcome the limitations they had observed in the use of their ELISA assays.

For research use only. Not for use in diagnostic procedures.